Marc Hanauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marc Hanauer has a total of 303 co-authors. Here are the top co-authors by number of shared publications:
- David Lagorce
US14-Orphanet, Inserm, Paris, Île-de-France, France
6 shared publications - Ana Rath
Inserm, US14-Orphanet, Paris, France
5 shared publications - Caterina Lucano
US14-Orphanet, Inserm, Paris, Île-de-France, France
4 shared publications - Ada Hamosh
Department of Genetic Medicine (DGM), McKusick‐Nathans Institute Johns Hopkins University Baltimore MD USA
2 shared publications - Andreas Zankl
Bone Dysplasia Research Group, UQ Centre for Clinical Research (UQCCR), The University of Queensland, Australia
2 shared publications - Annie Olry
US14-Orphanet, Inserm, Paris, Île-de-France, France
2 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e84553
The Orphanet Nomenclature and Classification of Rare Diseases for Improved Patient Recognition and Data Interoperability: Qualitative and Quantitative Analysis.
Although individually uncommon, rare diseases (RDs) collectively affect an estimated 329-624 million people worldwide. There are over 6500 known RDs, 85% of which affect fewer than 1 person per million. Consequently, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across countries. However, RDs remain underrepresented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. This paper presents the Orphanet Nomenclature and Classification of RDs detailing its content, production and update methodology, and mappings to other semantic resources. It also provides an up-to-date count of RDs based on the consensus operational definition describing their distribution by medical domain. The Orphanet Nomenclature of RDs is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into 3 classification levels organized within a multihierarchical and multiparental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation, and expert validation, reflecting advancements in RDs knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. As of July 2025, the Orphanet Nomenclature of RDs includes a total of 9784 active clinical entities, including 6527 disorders (corresponding to the RDs definition), 1084 subtypes of disorders, and 2173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RDs. Extensive qualified mappings ensure semantic interoperability: 97.4% (6355/6527) of disorders are mapped to at least 1 ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (415/6527, 6.4% with an exact proximity relationship), 71.8% (4683/6527) are mapped to at least 1 ICD-11 (International Classification of Diseases, Eleventh Revision) Mortality and Morbidity Statistics code (958/6527, 14.7% with an exact relationship) and 94.8% (6191/6527) are mapped to Systematized Nomenclature of Medicine Clinical Terms (all with an exact relationship). Genetic disorders represent 72.2% (4715/6527) of all RDs, and 63.4% (4141/6527) are mapped to at least 1 phenotypic Online Mendelian Inheritance in Man number. The Orphanet Nomenclature and Classification of RDs is the only RDs-specific interoperable medical terminology meeting the needs of health care, research, and public health systems. By addressing the underrepresentation of RDs in medical terminologies, it enables accurate RDs identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policymaking, and ultimately better care for people living with an RD.
- 8 July 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e84553
Open AccessThe Orphanet Nomenclature and Classification of Rare Diseases for Improved Patient Recognition and Data Interoperability: Qualitative and Quantitative Analysis.
Although individually uncommon, rare diseases (RDs) collectively affect an estimated 329-624 million people worldwide. There are over 6500 known RDs, 85% of which affect fewer than 1 person per million. Consequently, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across countries. However, RDs remain underrepresented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. This paper presents the Orphanet Nomenclature and Classification of RDs detailing its content, production and update methodology, and mappings to other semantic resources. It also provides an up-to-date count of RDs based on the consensus operational definition describing their distribution by medical domain. The Orphanet Nomenclature of RDs is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into 3 classification levels organized within a multihierarchical and multiparental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation, and expert validation, reflecting advancements in RDs knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. As of July 2025, the Orphanet Nomenclature of RDs includes a total of 9784 active clinical entities, including 6527 disorders (corresponding to the RDs definition), 1084 subtypes of disorders, and 2173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RDs. Extensive qualified mappings ensure semantic interoperability: 97.4% (6355/6527) of disorders are mapped to at least 1 ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (415/6527, 6.4% with an exact proximity relationship), 71.8% (4683/6527) are mapped to at least 1 ICD-11 (International Classification of Diseases, Eleventh Revision) Mortality and Morbidity Statistics code (958/6527, 14.7% with an exact relationship) and 94.8% (6191/6527) are mapped to Systematized Nomenclature of Medicine Clinical Terms (all with an exact relationship). Genetic disorders represent 72.2% (4715/6527) of all RDs, and 63.4% (4141/6527) are mapped to at least 1 phenotypic Online Mendelian Inheritance in Man number. The Orphanet Nomenclature and Classification of RDs is the only RDs-specific interoperable medical terminology meeting the needs of health care, research, and public health systems. By addressing the underrepresentation of RDs in medical terminologies, it enables accurate RDs identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policymaking, and ultimately better care for people living with an RD.
- Open Access
Combining phenotypic similarity and network propagation to improve performance and clinical consistency of rare disease diagnosis
Achieving timely diagnosis for rare diseases remains challenging due to, among others, phenotypic heterogeneity and incomplete clinical data. While the Solve-RD project developed a phenotype-based gene prioritisation method, this approach did not account for the clinical consistency among related diseases in Orphanet’s hierarchical classifications. We present a phenotype-based computational pipeline that ranks candidate ORPHAcodes based on patient phenotypes. The pipeline computes patient-disease similarity using asymmetric semantic aggregation of Human Phenotype Ontology terms, filtering subsumed terms and incorporating Orphanet frequency annotations. Evaluated on 139 expert curated Solve-RD cases representing 78 distinct ORPHAcodes, our methodology outperformed the established Solve-RD baseline method, achieving a harmonic mean rank of 4.64 for confirmed diagnoses (versus 7.97) and retrieving the correct suspected rare disease within the top 10 positions for 39% of patients (versus 29%). We then explore a disease similarity network using Random Walk with Restart to generate ranked candidate lists. Two complementary experiments demonstrate that RWR-ranked candidates exhibited improved clinical consistency, reflected by their proximity within the Orphanet nomenclature of rare diseases. This approach provides more interpretable and actionable differential diagnosis hypotheses to guide clinical decision-making Author summary: Many patients with rare diseases face prolonged diagnostic delays due to the extreme heterogeneity of rare disorders associated with the variability of their clinical manifestations, which complicates interpretation and requires structured phenotypic representations and expert knowledge. We developed a computational pipeline that compares patients’ phenotypes with those documented for rare diseases in the Orphanet database. Rather than relying solely on direct matching of clinical signs and symptoms, our approach leverages relationships between diseases by propagating information through a network connecting patients and diseases. Testing on 139 cases from the European Solve-RD project, our method improved identification of correct diagnoses and generated more clinically coherent candidate lists by accounting the Orphanet nomenclature. This work provides a methodology dedicated to assisting clinicians in developing diagnostic hypotheses for rare diseases.
Open AccessCombining phenotypic similarity and network propagation to improve performance and clinical consistency of rare disease diagnosis
Achieving timely diagnosis for rare diseases remains challenging due to, among others, phenotypic heterogeneity and incomplete clinical data. While the Solve-RD project developed a phenotype-based gene prioritisation method, this approach did not account for the clinical consistency among related diseases in Orphanet’s hierarchical classifications. We present a phenotype-based computational pipeline that ranks candidate ORPHAcodes based on patient phenotypes. The pipeline computes patient-disease similarity using asymmetric semantic aggregation of Human Phenotype Ontology terms, filtering subsumed terms and incorporating Orphanet frequency annotations. Evaluated on 139 expert curated Solve-RD cases representing 78 distinct ORPHAcodes, our methodology outperformed the established Solve-RD baseline method, achieving a harmonic mean rank of 4.64 for confirmed diagnoses (versus 7.97) and retrieving the correct suspected rare disease within the top 10 positions for 39% of patients (versus 29%). We then explore a disease similarity network using Random Walk with Restart to generate ranked candidate lists. Two complementary experiments demonstrate that RWR-ranked candidates exhibited improved clinical consistency, reflected by their proximity within the Orphanet nomenclature of rare diseases. This approach provides more interpretable and actionable differential diagnosis hypotheses to guide clinical decision-making Author summary: Many patients with rare diseases face prolonged diagnostic delays due to the extreme heterogeneity of rare disorders associated with the variability of their clinical manifestations, which complicates interpretation and requires structured phenotypic representations and expert knowledge. We developed a computational pipeline that compares patients’ phenotypes with those documented for rare diseases in the Orphanet database. Rather than relying solely on direct matching of clinical signs and symptoms, our approach leverages relationships between diseases by propagating information through a network connecting patients and diseases. Testing on 139 cases from the European Solve-RD project, our method improved identification of correct diagnoses and generated more clinically coherent candidate lists by accounting the Orphanet nomenclature. This work provides a methodology dedicated to assisting clinicians in developing diagnostic hypotheses for rare diseases.
- Open Access
- 22 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
The Orphanet Nomenclature and Classification of Rare Diseases for Improved Patient Recognition and Data Interoperability: Qualitative and Quantitative Analysis (Preprint)
BACKGROUND Although individually uncommon, rare diseases (RDs) collectively affect an estimated 329-624 million people worldwide. There are over 6500 known RDs, 85% of which affect fewer than 1 person per million. Consequently, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across countries. However, RDs remain underrepresented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. OBJECTIVE This paper presents the Orphanet Nomenclature and Classification of RDs detailing its content, production and update methodology, and mappings to other semantic resources. It also provides an up-to-date count of RDs based on the consensus operational definition describing their distribution by medical domain. METHODS The Orphanet Nomenclature of RDs is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into 3 classification levels organized within a multihierarchical and multiparental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation, and expert validation, reflecting advancements in RDs knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. RESULTS As of July 2025, the Orphanet Nomenclature of RDs includes a total of 9784 active clinical entities, including 6527 disorders (corresponding to the RDs definition), 1084 subtypes of disorders, and 2173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RDs. Extensive qualified mappings ensure semantic interoperability: 97.4% (6355/6527) of disorders are mapped to at least 1 ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (415/6527, 6.4% with an exact proximity relationship), 71.8% (4683/6527) are mapped to at least 1 ICD-11 (International Classification of Diseases, Eleventh Revision) Mortality and Morbidity Statistics code (958/6527, 14.7% with an exact relationship) and 94.8% (6191/6527) are mapped to Systematized Nomenclature of Medicine Clinical Terms (all with an exact relationship). Genetic disorders represent 72.2% (4715/6527) of all RDs, and 63.4% (4141/6527) are mapped to at least 1 phenotypic Online Mendelian Inheritance in Man number. CONCLUSIONS The Orphanet Nomenclature and Classification of RDs is the only RDs-specific interoperable medical terminology meeting the needs of health care, research, and public health systems. By addressing the underrepresentation of RDs in medical terminologies, it enables accurate RDs identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policymaking, and ultimately better care for people living with an RD. CLINICALTRIAL
- 22 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Orphanet Nomenclature and Classification of Rare Diseases for Improved Patient Recognition and Data Interoperability: Qualitative and Quantitative Analysis (Preprint)
BACKGROUND Although individually uncommon, rare diseases (RDs) collectively affect an estimated 329-624 million people worldwide. There are over 6500 known RDs, 85% of which affect fewer than 1 person per million. Consequently, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across countries. However, RDs remain underrepresented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. OBJECTIVE This paper presents the Orphanet Nomenclature and Classification of RDs detailing its content, production and update methodology, and mappings to other semantic resources. It also provides an up-to-date count of RDs based on the consensus operational definition describing their distribution by medical domain. METHODS The Orphanet Nomenclature of RDs is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into 3 classification levels organized within a multihierarchical and multiparental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation, and expert validation, reflecting advancements in RDs knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. RESULTS As of July 2025, the Orphanet Nomenclature of RDs includes a total of 9784 active clinical entities, including 6527 disorders (corresponding to the RDs definition), 1084 subtypes of disorders, and 2173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RDs. Extensive qualified mappings ensure semantic interoperability: 97.4% (6355/6527) of disorders are mapped to at least 1 ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (415/6527, 6.4% with an exact proximity relationship), 71.8% (4683/6527) are mapped to at least 1 ICD-11 (International Classification of Diseases, Eleventh Revision) Mortality and Morbidity Statistics code (958/6527, 14.7% with an exact relationship) and 94.8% (6191/6527) are mapped to Systematized Nomenclature of Medicine Clinical Terms (all with an exact relationship). Genetic disorders represent 72.2% (4715/6527) of all RDs, and 63.4% (4141/6527) are mapped to at least 1 phenotypic Online Mendelian Inheritance in Man number. CONCLUSIONS The Orphanet Nomenclature and Classification of RDs is the only RDs-specific interoperable medical terminology meeting the needs of health care, research, and public health systems. By addressing the underrepresentation of RDs in medical terminologies, it enables accurate RDs identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policymaking, and ultimately better care for people living with an RD. CLINICALTRIAL
- Open Access
The Orphanet Nomenclature and Classification of rare diseases: a standard terminology for improved patient recognition and data interoperability
Background: Although individually uncommon, rare diseases (RD) collectively affect an estimated 329-624 million people worldwide There are over 6,500 known RD, 85% of which affect fewer than 1 person per million. As a result, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across different countries in a standardized manner. However, RD are under-represented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. Objective: The aim of this paper is to present the Orphanet Nomenclature and Classification of RD. We detail its content as well as its production and update methodology, and an overview of its mappings to other semantic resources. In addition, this work provides a clear and up-to-date count of RD based on the consensus operational definition of RD, and it details the distribution of RD by medical domain. Methods: The Orphanet Nomenclature of RD is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into three classification levels organized within a multi-hierarchical and multi-parental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation and expert validation, reflecting advancements in RD knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. Results: As of July 2025, the Orphanet Nomenclature of RD includes a total of 9,784 active clinical entities, including 6,527 disorders (corresponding to the RD definition), 1,084 subtypes of disorders, and 2,173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RD. Extensive qualified mappings ensure semantic interoperability: 97.4% of disorders are mapped to at least one ICD-10 code (6.4% with an exact proximity relationship), 71.8% are mapped to at least one ICD-11 MMS code (14.7% with an exact relationship) and 94.8% are mapped to SNOMED CT (all with an exact relationship). Genetic disorders represent 72.2% of all RD, and 63.4% are mapped to at least one phenotypic OMIM number. Conclusions: The Orphanet Nomenclature and Classification of RD is the only RD-specific interoperable medical terminology meeting the needs of healthcare, research, and public health systems. By addressing the underrepresentation of RD in medical terminologies, it enables accurate RD identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policy-making, and ultimately better care for people living with a RD.
Open AccessThe Orphanet Nomenclature and Classification of rare diseases: a standard terminology for improved patient recognition and data interoperability
Background: Although individually uncommon, rare diseases (RD) collectively affect an estimated 329-624 million people worldwide There are over 6,500 known RD, 85% of which affect fewer than 1 person per million. As a result, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across different countries in a standardized manner. However, RD are under-represented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. Objective: The aim of this paper is to present the Orphanet Nomenclature and Classification of RD. We detail its content as well as its production and update methodology, and an overview of its mappings to other semantic resources. In addition, this work provides a clear and up-to-date count of RD based on the consensus operational definition of RD, and it details the distribution of RD by medical domain. Methods: The Orphanet Nomenclature of RD is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into three classification levels organized within a multi-hierarchical and multi-parental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation and expert validation, reflecting advancements in RD knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. Results: As of July 2025, the Orphanet Nomenclature of RD includes a total of 9,784 active clinical entities, including 6,527 disorders (corresponding to the RD definition), 1,084 subtypes of disorders, and 2,173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RD. Extensive qualified mappings ensure semantic interoperability: 97.4% of disorders are mapped to at least one ICD-10 code (6.4% with an exact proximity relationship), 71.8% are mapped to at least one ICD-11 MMS code (14.7% with an exact relationship) and 94.8% are mapped to SNOMED CT (all with an exact relationship). Genetic disorders represent 72.2% of all RD, and 63.4% are mapped to at least one phenotypic OMIM number. Conclusions: The Orphanet Nomenclature and Classification of RD is the only RD-specific interoperable medical terminology meeting the needs of healthcare, research, and public health systems. By addressing the underrepresentation of RD in medical terminologies, it enables accurate RD identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policy-making, and ultimately better care for people living with a RD.
- Open Access
- 22 August 2024
- Published by IOS Press
- Vol. 316, 1442-1446
Privacy-Preserving Linkage of Distributed Pseudonymised Datasets in a Virtual European Rare Disease Platform
Secondary use of data for research purposes is especially important in rare diseases (RD), since, per definition, data are sparse. The European Joint Programme on Rare Diseases (EJP RD) aims at developing an RD infrastructure which supports the secondary use of data. Significant amounts of RD data are a) distributed and b) available only in pseudonymised format. Privacy-Preserving Record Linkage (PPRL) concerns the linking of such distributed datasets without disclosing the participant’s identities. We present a concept for linking a PPRL Service to the EJP RD Virtual Platform (VP). Level 1 (resource discovery) connection is provided by running an FDP within the PPRL Service. On Level 2 (data discoverability), the PPRL Service can represent both, an individual and a catalog endpoint. Our solution can count patients in PPRL-supporting resources, count duplicates only once, and count only patients registered to multiple resources. Currently, we are preparing the deployment within the EJP RD VP.
- 22 August 2024
- Published by IOS Press
- Vol. 316, 1442-1446
Open AccessPrivacy-Preserving Linkage of Distributed Pseudonymised Datasets in a Virtual European Rare Disease Platform
Secondary use of data for research purposes is especially important in rare diseases (RD), since, per definition, data are sparse. The European Joint Programme on Rare Diseases (EJP RD) aims at developing an RD infrastructure which supports the secondary use of data. Significant amounts of RD data are a) distributed and b) available only in pseudonymised format. Privacy-Preserving Record Linkage (PPRL) concerns the linking of such distributed datasets without disclosing the participant’s identities. We present a concept for linking a PPRL Service to the EJP RD Virtual Platform (VP). Level 1 (resource discovery) connection is provided by running an FDP within the PPRL Service. On Level 2 (data discoverability), the PPRL Service can represent both, an individual and a catalog endpoint. Our solution can count patients in PPRL-supporting resources, count duplicates only once, and count only patients registered to multiple resources. Currently, we are preparing the deployment within the EJP RD VP.
- Open Access
- 1 May 2024
- Published by China Science Publishing & Media Ltd. in Data Intelligence
- Vol. 6 (2) , 429-456
Building Expertise on FAIR Through Evolving Bring Your Own Data (BYOD) Workshops: Describing the Data, Software, and Management-focused Approaches and Their Evolution
Since 2014, “Bring Your Own Data” workshops (BYODs) have been organised to inform people about the process and benefits of making resources Findable, Accessible, Interoperable, and Reusable (FAIR, and the FAIRification process). The BYOD workshops’ content and format differ depending on their goal, context, and the background and needs of participants. Data-focused BYODs educate domain experts on how to make their data FAIR to find new answers to research questions. Management-focused BYODs promote the benefits of making data FAIR and instruct project managers and policy-makers on the characteristics of FAIRification projects. Software-focused BYODs gather software developers and experts on FAIR to implement or improve software resources that are used to support FAIRification. Overall, these BYODs intend to foster collaboration between different types of stakeholders involved in data management, curation, and reuse (e.g. domain experts, trainers, developers, data owners, data analysts, FAIR experts). The BYODs also serve as an opportunity to learn what kind of support for FAIRification is needed from different communities and to develop teaching materials based on practical examples and experience. In this paper, we detail the three different structures of the BYODs and describe examples of early BYODs related to plant breeding data, and rare disease registries and biobanks, which have shaped the structure of the workshops. We discuss the latest insights into making BYODs more productive by leveraging our almost ten years of training experience in these workshops, including successes and encountered challenges. Finally, we examine how the participants’ feedback has motivated the research on FAIR, including the development of workflows and software.
- 1 May 2024
- Published by China Science Publishing & Media Ltd. in Data Intelligence
- Vol. 6 (2) , 429-456
Open AccessBuilding Expertise on FAIR Through Evolving Bring Your Own Data (BYOD) Workshops: Describing the Data, Software, and Management-focused Approaches and Their Evolution
Since 2014, “Bring Your Own Data” workshops (BYODs) have been organised to inform people about the process and benefits of making resources Findable, Accessible, Interoperable, and Reusable (FAIR, and the FAIRification process). The BYOD workshops’ content and format differ depending on their goal, context, and the background and needs of participants. Data-focused BYODs educate domain experts on how to make their data FAIR to find new answers to research questions. Management-focused BYODs promote the benefits of making data FAIR and instruct project managers and policy-makers on the characteristics of FAIRification projects. Software-focused BYODs gather software developers and experts on FAIR to implement or improve software resources that are used to support FAIRification. Overall, these BYODs intend to foster collaboration between different types of stakeholders involved in data management, curation, and reuse (e.g. domain experts, trainers, developers, data owners, data analysts, FAIR experts). The BYODs also serve as an opportunity to learn what kind of support for FAIRification is needed from different communities and to develop teaching materials based on practical examples and experience. In this paper, we detail the three different structures of the BYODs and describe examples of early BYODs related to plant breeding data, and rare disease registries and biobanks, which have shaped the structure of the workshops. We discuss the latest insights into making BYODs more productive by leveraging our almost ten years of training experience in these workshops, including successes and encountered challenges. Finally, we examine how the participants’ feedback has motivated the research on FAIR, including the development of workflows and software.
- Top Cited PapersOpen Access
- 11 November 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D1333-D1346
The Human Phenotype Ontology in 2024: phenotypes around the world
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.
- 11 November 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D1333-D1346
Top Cited PapersOpen AccessThe Human Phenotype Ontology in 2024: phenotypes around the world
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.
- Top Cited PapersOpen Access
Mondo: Unifying diseases for the world, by the world
There are thousands of distinct disease entities and concepts, each of which are known by different and sometimes contradictory names. The lack of a unified system for managing these entities poses a major challenge for both machines and humans that need to harmonize information to better predict causes and treatments for disease. The Mondo Disease Ontology is an open, community-driven ontology that integrates key medical and biomedical terminologies, supporting disease data integration to improve diagnosis, treatment, and translational research. Mondo records the sources of all data and is continually updated, making it suitable for research and clinical applications that require up-to-date disease knowledge.
Top Cited PapersOpen AccessMondo: Unifying diseases for the world, by the world
There are thousands of distinct disease entities and concepts, each of which are known by different and sometimes contradictory names. The lack of a unified system for managing these entities poses a major challenge for both machines and humans that need to harmonize information to better predict causes and treatments for disease. The Mondo Disease Ontology is an open, community-driven ontology that integrates key medical and biomedical terminologies, supporting disease data integration to improve diagnosis, treatment, and translational research. Mondo records the sources of all data and is continually updated, making it suitable for research and clinical applications that require up-to-date disease knowledge.